CTOs on the Move

Genewiz Inc

www.genewiz.com

 
Genewiz Inc is a South Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.genewiz.com
  • 115 Corporate Blvd
    South Plainfield, NJ USA 07080
  • Phone: 877.436.3949

Executives

Name Title Contact Details

Similar Companies

ARIAD Pharmaceuticals, Inc.

ARIAD is a pharmaceutical company whose vision is to transform the lives of cancer patients with breakthrough medicines.

Spheryx

Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic CharacterizationTM of colloidal materials. Spheryx’s breakthrough proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, thereby offering unprecedented insights into these materials’ characteristics. Applications include research and development, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs.

Healthtech Holdings

HealthTech Holdings Inc. is a health information technology holding company that owns Healthcare Management Systems, MEDHOST and Sentry Healthcare Services.

G1 Therapeutics

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company`s pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer.

ADS

ADS is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.